Related Experiment Video
Updated: Jul 5, 2026

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
Published on: January 7, 2022
Inhibitors of UDP-galactopyranose mutase thwart mycobacterial growth
Emily C Dykhuizen1, John F May, Aimon Tongpenyai
1Departments of Chemistry and Biochemistry, University of WisconsinMadison, Madison, Wisconsin 53706, USA.
Abstract:
Galactofuranose (Galf) residues are fundamental components of the cell wall of mycobacteria. A key enzyme, UDP-galactopyranose mutase (UGM), that participates in Galf incorporation mediates isomerization of UDP-Galf from UDP-galactopyranose (UDP-Galp). UGM is of special interest as a therapeutic target because the gene encoding it is essential for mycobacterial viability and there is no comparable enzyme in humans. We used structure-activity relationships and molecular design to devise UGM inhibitors. From a focused library of synthetic aminothiazoles, several compounds that block the UGM from Klebsiella pneumoniae or Mycobacterium tuberculosis were identified. These inhibitors block the growth of M. smegmatis.
Insights
Researchers identified novel aminothiazole inhibitors targeting UDP-galactopyranose mutase (UGM), an essential enzyme in mycobacteria. These compounds effectively block bacterial growth, offering a potential therapeutic strategy against mycobacterial infections.
Area of Science:
- Microbiology
- Medicinal Chemistry
- Biochemistry
Background:
- Galactofuranose (Galf) is crucial for mycobacterial cell walls.
- UDP-galactopyranose mutase (UGM) synthesizes Galf and is essential for mycobacteria.
- UGM is a promising therapeutic target due to its absence in humans.
Purpose of the Study:
- To design and identify novel inhibitors of UDP-galactopyranose mutase (UGM).
- To explore structure-activity relationships for developing effective UGM inhibitors.
- To assess the efficacy of identified inhibitors against mycobacterial growth.
Main Methods:
- Structure-activity relationship (SAR) studies.
- Molecular design and synthesis of aminothiazole compounds.
- Enzyme inhibition assays for UGM from Klebsiella pneumoniae and Mycobacterium tuberculosis.
- Assessment of inhibitor activity against Mycobacterium smegmatis growth.
Main Results:
- Several synthetic aminothiazole derivatives were identified as potent UGM inhibitors.
- Inhibitors demonstrated efficacy against UGM from both K. pneumoniae and M. tuberculosis.
- The identified compounds successfully inhibited the growth of M. smegmatis.
Conclusions:
- Aminothiazoles represent a promising class of compounds for targeting mycobacterial UGM.
- Inhibiting UGM is a viable strategy for developing new anti-mycobacterial therapeutics.
- These findings support further development of UGM inhibitors for treating mycobacterial diseases.
Related Concept Videos
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial DNA Synthesis
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Feedback Inhibition

